LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?

被引：18

作者：

Besseling, Joost ^{[1
]}

van Capelleveen, Julian ^{[1
]}

Kastelein, John J. P. ^{[1
]}

Hovingh, G. Kees ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands

来源：

DRUGS | 2013年 / 73卷 / 04期

关键词：

DENSITY-LIPOPROTEIN CHOLESTEROL; CHRONIC KIDNEY-DISEASE; TRIGLYCERIDE TRANSFER PROTEIN; PRIMARY PREVENTION; FAMILIAL HYPERCHOLESTEROLEMIA; MYOCARDIAL-INFARCTION; INTERVENTION TRIAL; CORONARY EVENTS; PLUS EZETIMIBE; HEART-DISEASE;

D O I：

10.1007/s40265-013-0028-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies.

引用

页码：293 / 301

页数：9

共 59 条

[1] Mutations and Polymorphisms in the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease [J].

Abifadel, Marianne ;

Rabes, Jean-Pierre ;

Devillers, Martine ;

Munnich, Arnold ;

Erlich, Daniele ;

Junien, Claudine ;

Varret, Mathilde ;

Boileau, Catherine .

HUMAN MUTATION, 2009, 30 (04) :520-529

[2]

[Anonymous], 2008, CLIN GUIDELINES EVID

[3] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[4] The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial [J].

Baigent, Colin ;

Landray, Martin J. ;

Reith, Christina ;

Emberson, Jonathan ;

Wheeler, David C. ;

Tomson, Charles ;

Wanner, Christoph ;

Krane, Vera ;

Cass, Alan ;

Craig, Jonathan ;

Neal, Bruce ;

Jiang, Lixin ;

Hooi, Lai Seong ;

Levin, Adeera ;

Agodoa, Lawrence ;

Gaziano, Mike ;

Kasiske, Bertram ;

Walker, Robert ;

Massy, Ziad A. ;

Feldt-Rasmussen, Bo ;

Krairittichai, Udom ;

Ophascharoensuk, Vuddidhej ;

Fellstrom, Bengt ;

Holdaas, Hallvard ;

Tesar, Vladimir ;

Wiecek, Andrzej ;

Grobbee, Diederick ;

de Zeeuw, Dick ;

Gronhagen-Riska, Carola ;

Dasgupta, Tanaji ;

Lewis, David ;

Herrington, William ;

Mafham, Marion ;

Majoni, William ;

Wallendszus, Karl ;

Grimm, Richard ;

Pedersen, Terje ;

Tobert, Jonathan ;

Armitage, Jane ;

Baxter, Alex ;

Bray, Christopher ;

Chen, Yiping ;

Chen, Zhengming ;

Hill, Michael ;

Knott, Carol ;

Parish, Sarah ;

Simpson, David ;

Sleight, Peter ;

Young, Alan ;

Collins, Rory .

LANCET, 2011, 377 (9784) :2181-2192

[5] Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[6] Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].

Boden, William E. ;

Probstfield, Jeffrey L. ;

Anderson, Todd ;

Chaitman, Bernard R. ;

Desvignes-Nickens, Patrice ;

Koprowicz, Kent ;

McBride, Ruth ;

Teo, Koon ;

Weintraub, William .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267

[7] A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS [J].

BROWN, MS ;

GOLDSTEIN, JL .

SCIENCE, 1986, 232 (4746) :34-47

[8] Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. [J].

Cannon, Christopher P. ;

Shah, Sukrut ;

Dansky, Hayes M. ;

Davidson, Michael ;

Brinton, Eliot A. ;

Gotto, Antonio M., Jr. ;

Stepanavage, Michael ;

Liu, Sherry Xueyu ;

Gibbons, Patrice ;

Ashraf, Tanya B. ;

Zafarino, Jennifer ;

Mitchel, Yale ;

Barter, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (25) :2406-2415

[9] Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].

Cannon, CP ;

Braunwald, E ;

McCabe, CH ;

Rader, DJ ;

Rouleau, JL ;

Belder, R ;

Joyal, SV ;

Hill, KA ;

Pfeffer, MA ;

Skene, AM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504

[10] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].

Colhoun, HM ;

Betteridge, DJ ;

Durrington, PN ;

Hitman, GA ;

Neil, HAW ;

Livingstone, SJ ;

Thomason, MJ ;

Mackness, MI ;

Charlton-Menys, V ;

Fuller, JH .

LANCET, 2004, 364 (9435) :685-696

← 1 2 3 4 5 6 →